Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 486-492 , October 2009

GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study

  • M Melo

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • Corresponding Author InformationCorrespondence:
    • ,
  • CE Busso

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • ,
  • J Bellver

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • ,
  • P Alama

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • ,
  • N Garrido

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • Fundación IVI, Valencia 46015, Spain
    • ,
  • M Meseguer

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • Fundación IVI, Valencia 46015, Spain
    • ,
  • A Pellicer

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain
    • Fundación IVI, Valencia 46015, Spain
    • Department of Obstetrics and Gynaecology, University Hospital Dr. Peset, Valencia 46017, Spain
    • ,
  • J Remohí

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia 46015, Spain

Received 3 September 2008 ,Revised 3 December 2008 ,Accepted 1 January 2009.

References 

  1. Acevedo B, Gomez-Palomares JL, Ricciarelli E, et al. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertility and Sterility. 2006;86:1682–1687
  2. Alikani M, Calderón G, Tomkin G, et al. Cleavage anomalies in early human embryos and survival after prolonged culture in vitro. Human Reproduction. 2000;15:2634–2643
  3. Andersen CY, Humaidan P, Ejdrup HB, et al. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Human Reproduction. 2006;21:2126–2130
  4. Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction. 2006;21:1260–1265
  5. Balasch J, Tur R, Creus M, et al. Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecological Endocrinology. 1994;8:7–12
  6. Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Journal of Clinical Endocrinology and Metabolism. 2003;88:4186–4192
  7. Bentick B, Shaw RW, Iffland CA, et al. IVF pregnancy after induction of an ovulatory endogenous gonadotrophin surge using an LHRH agonist nasal spray. Human Reproduction. 1990;5:570–572
  8. Buckett WM, Bentick B, Shaw RW. Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose. Human Reproduction. 1998;13:811–814
  9. de Jong D, Van Hooren EG, Macklon NS, et al. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report. Journal of Assisted Reproduction and Genetics. 2001;18:30–33
  10. Eldar-Geva T, Zylber-Haran E, Babayof R, et al. Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation. Reproductive BioMedicine Online. 2007;14:148–154
  11. Emperaire JC, Ruffie A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Human Reproduction. 1991;6:506–510
  12. Emperaire JC, Parneix I, Ruffie A. Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reproductive BioMedicine Online. 2004;9:22–27
  13. Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and Sterility. 2008;89:84–91
  14. Engmann L, Siano L, Schmidt D, et al. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reproductive BioMedicine Online. 2006;13:639–644
  15. Fauser BC, de Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism. 2002;87:709–715
  16. Garrido N, Zuzuarregui JL, Meseguer M, et al. Sperm and oocyte selection and management: experience of a 10 year follow-up of more than 2100 candidates. Human Reproduction. 2002;17:3142–3147
  17. Golan A, Ron-El R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey. 1989;44:430–440
  18. Griesinger G, Kolibianakis EM, Papanikolaou EG, et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertility and Sterility. 2007;88:616–621
  19. Griesinger G, Diedrich K, Devroey P, et al. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Human Reproduction Update. 2006;12:159–168
  20. Humaidan P, Bungum L, Bungum M, et al. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online. 2006;13:173–178
  21. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction. 2005;20:1213–1220
  22. Itskovitz JE, Boldes R, Levron J, et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertility and Sterility. 1991;56:213–220
  23. Kol S, Lewit N, Itskovitz JE. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Human Reproduction. 1996;11:1143–1148
  24. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction. 2005;20:2887–2892
  25. Lambalk CB, Homburg R. GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution. Human Reproduction. 2006;21:2580–2582
  26. Lanzone A, Fulghesu AM, Villa P, et al. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertility and Sterility. 1994;62:35–41
  27. Lanzone A, Panetta V, Di Simone N, et al. Effect of gonadotrophin-releasing hormone and related analogue on human luteal cell function in vitro. Human Reproduction. 1989;4:906–909
  28. Lewit N, Kol S, Manor D, et al. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case–control study. Human Reproduction. 1996;11:1399–1402
  29. Melo MA, Meseguer M, Garrido N, et al. The significance of premature luteinization in an oocyte-donation programme. Human Reproduction. 2006;21:1503–1507
  30. Olivennes F, Fanchin R, Bouchard P, et al. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with GnRH antagonist. Fertility and Sterility. 1996;66:151–153
  31. Orvieto R, Rabinson J, Meltzer S, et al. Substituting HCG with GnRH agonist to trigger final follicular maturation – a retrospective comparison of three different ovarian stimulation protocols. Reproductive BioMedicine Online. 2006;13:198–201
  32. Tavaniotou A, Albano C, Smitz J, et al. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. Journal of Reproductive Immunology. 2002;55:123–130
  33. Tesarik J, Hazout A, Mendoza-Tesarik R, et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Human Reproduction. 2006;21:2572–2579

☆ Dr Marco Melo is a gynaecologist, specializing in reproductive medicine. He obtained his MD and PhD degrees at the Federal University of Minas Gerais, Brazil. During the last five years, he has been working as a specialist in reproduction at the Instituto Valenciano de Infertilidad, a university-affiliated infertility clinic of Valencia, Spain. Moreover, since 2005, he has been involved in teaching the Masters degree in Reproductive Biotechnology from the Instituto Universitario IVI, Valencia University. He is author and co-author of several publications and book chapters. His research interests include reproductive endocrinology, embryo implantation and ovarian induction protocols.Dr Melo

PII: S1472-6483(09)00010-8

doi: 10.1016/j.rbmo.2009.06.001

Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 486-492 , October 2009

Article Tools

* Image Usage & Resolution